BHU study on Covaxin had serious methodological flaws as per ICMR: Prataprao Jadhav

The Indian Council of Medical Research (ICMR) reviewed a study on the long-term safety of Covaxin in adults and adolescents, conducted by Banaras Hindu University, and found significant methodological flaws. Minister of State for Health Prataprao Jadhav informed the Rajya Sabha that the study lacked a control group of unvaccinated individuals, making it impossible to link reported events to the vaccine. The study, published in May, also lacked background rates and baseline participant information. ICMR has requested the removal of its acknowledgment from the study and asked the journal to retract the paper due to unsupported conclusions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ClH27uW
via IFTTT

Read More

Pharma industry urges govt for stable drug pricing policy

The Organisation of Pharmaceutical Producers of India (OPPI) has called for a stable and predictable drug pricing policy, urging the government to avoid using Para 19 of the Drug Pricing Control Order (DPCO), which allows significant price reductions in the public interest.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/muJ9vQw
via IFTTT

Read More

Hamara Hospital! Bajaj plans a healthcare ride

The Bajaj Group, worth ₹1.46 lakh crore, initiated steps to venture into the healthcare industry by setting up hospitals in metros. Overseen by Nirav Bajaj, the project will be housed in a new company, with phased investments based on milestones. This marks the group's first major diversification since Rahul Bajaj's death in 2022.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EzQ1l3D
via IFTTT

Read More

New data reveals why patients from the US and UK are flocking to India for organ transplants

In 2023, India conducted 1,851 organ transplants for foreign nationals, accounting for nearly 10% of all transplants. The majority of these transplants took place in Delhi, Rajasthan, and West Bengal. Foreign patients primarily seek living donor transplants due to lower costs and strict vetting protocols. Deceased donations are rare and usually reserved for Indian recipients. India set records with over 1,000 deceased donors and 18,378 transplants, highlighting its growing role as a hub for organ transplants.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ULAde19
via IFTTT

Read More

Sun Pharma's hair loss drug in the cross hairs in US

Leqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and Drug Administration (USFDA) last week. Sun Pharma has been making preparations for months to launch the drug in July, but an injunction motion by the American drugmaker lncyte Corporation in the US District Court for the District of New Jersey has put the brakes on the launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwrhX9v
via IFTTT

Read More

Bharat Biotech credited ICMR, NIV as Covaxin co-inventors after missing them initially: Government

Responding to Trinamool Congress member Sougata Roy, who had asked whether the government took any punitive action against the company for not mentioning the names of ICMR and NIV in the patent application, the Union Health and Family Welfare Minister gave a detailed reply. There was a joint Memorandum of Understanding (MoU) between ICMR, NIV and Bharat Biotech for the development of Covaxin, he said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yjXgSFt
via IFTTT

Read More

Sanofi gets drug regulator nod to market RSV therapy in India

French drugmaker Sanofi announced on Thursday that it has received approval from India's Central Drugs Standard Control Organization (CDSCO) to market its novel therapy, Beyfortus, in India. The therapy is aimed at protecting newborns and infants from respiratory syncytial virus (RSV).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0YUjf7
via IFTTT

Read More